Increased sensitivity to GANT61 was detected following either genetic inactivation of AMPKα1 or pharmacological inhibition of AMPK by Compound C. Moreover, combined targeting of HH and AMPK signaling pathways in T-ALL cells by GANT61 and SBI-0206965 (another AMPK inhibitor) significantly increased the cytotoxic effects of the drugs [238]. The gene discussed is PRKAA1; the disease is acute lymphoblastic leukemia.